APA (7th ed.) Citation

Beaumont, K., Pike, A., Davies, M., Savoca, A., Vasalou, C., Harlfinger, S., . . . McGinnity, D. (2022). ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs). Xenobiotica, 52(8), 770. https://doi.org/10.1080/00498254.2022.2141667

Chicago Style (17th ed.) Citation

Beaumont, Kevin, et al. "ADME and DMPK Considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs)." Xenobiotica 52, no. 8 (2022): 770. https://doi.org/10.1080/00498254.2022.2141667.

MLA (9th ed.) Citation

Beaumont, Kevin, et al. "ADME and DMPK Considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs)." Xenobiotica, vol. 52, no. 8, 2022, p. 770, https://doi.org/10.1080/00498254.2022.2141667.